3 4 3. VALIDITY AND RESERVATION OF WARRANT SHARESOsi Pharmaceuticals Inc • December 29th, 1997 • In vitro & in vivo diagnostic substances • Delaware
1 Portions of this Exhibit 10.35 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT THIS AGREEMENT, dated this...Purchase Agreement • December 29th, 1997 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
1 Portions of this Exhibit 10.33 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 EXHIBIT A TO SUBSCRIPTION AGREEMENTLicense and Services Agreement • December 29th, 1997 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
1 Portions of this Exhibit 10.34 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 STOCKHOLDERS' AGREEMENT THIS STOCKHOLDERS' AGREEMENT, dated July 17, 1997...Stockholders' Agreement • December 29th, 1997 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
1 Portions of this Exhibit 10.36 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT This COLLABORATIVE RESEARCH...And License Agreement • December 29th, 1997 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
